ARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC.
Business updates for various pharma and life science companies around the globe.
Machine learning and artificial intelligence (AI) may resoundingly improve on traditional methods of drug development by biopharmaceutical companies.
The U.S. Food and Drug Administration rejected Sunovion Pharmaceuticals’ experimental treatment apomorphine sublingual film (APL-130277) for OFF episodes of Parkinson’s disease.
Privately held Tizona Therapeutics snagged $105 million in upfront cash as the company’s cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.
A potential rival for Allergan Plc’s blockbuster Botox passed a late-stage study, putting drug developer Revance Therapeutics Inc. on course to file for U.S. marketing approval in 2019.
Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck, which will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs.
The U.S. FDA approved the New Drug Application of Xelpros 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, filed for an initial public offering (IPO) to raise $150 million.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.